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nasal cultures in 6 of the 11 members
of the 2 families. In this niche, it was
able to persist and cause a series of
infections in a relatively large number
of family members. Even though the
S. aureus isolated from active lesions
were not available for testing, the
recovery of identical PVL-positive
organisms from nasal cultures strong-
ly suggests the presence of a patho-
genic clone that probably caused the
recurrent infections in the 6 affected
family members. Our investigation
highlights the high transmissibility of
this PVL-producing S. aureus clone,
its high attack rate, and its virulence.
The intervention in this outbreak
might have prevented not only subse-
quent recurrences of cutaneous infec-
tions but also further spread of this
clone and the manifestation of even
more serious infections such as necro-
tizing pneumonia. Increasing aware-
ness among community-based health-
care providers of PVL-producing S.
aureus infections is important to facil-
itate rapid and adequate response in
similar clinical events in the future.
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Chikungunya Fever,
Hong Kong 
To the Editor: Chikungunya virus
disease, caused by a mosquitoborne
alphavirus, is endemic to Africa and
Southeast Asia. It typically causes an
acute febrile illness, with joint pain
and a skin rash. Chronic arthropathy
may develop (1,2). No treatment or
vaccine is available, and relatively lit-
tle research has been conducted into
its pathogenesis, compared with that
of other arboviruses, such as dengue.
Recent reports have described a mas-
sive outbreak of chikungunya disease
occurring on islands in the Indian
Ocean, off the east coast of Africa (1).
Reemergence of chikungunya has also
been reported from Indonesia (2).
During March 2006, a 66-year-old
Chinese man from Hong Kong visited
Mauritius where he was bitten by
mosquitoes 2 days before returning to
Hong Kong. On the return trip, he
experienced fever (39°C), severe fin-
ger joint and muscle pains, mild
headache, and a skin rash, and he
sought treatment at the Prince of
Wales Hospital (PWH) Infectious
Diseases Clinic on the second day of
his illness. Physical examination
showed a generalized erythematous
rash over the trunk and limbs and
petechiae over the lower limbs. Mild
finger joint stiffness was observed,
but no joint swelling. No lym-
phadenopathy or eschar was detected.
Level of C-reactive protein was ele-
vated at 10.4 mg/L. Results of screens
for malaria and dengue were negative.
Results of other routine assessments
were unremarkable. His symptoms
subsided gradually within a week.
Serum specimens taken on days 2
and 6 were positive for chikungunya
virus RNA by in-house reverse tran-
scription (RT)-PCR at the Public
Health Laboratory Service (PHLS)
(targeting the nonstructural protein-1
[NSP-1] gene) and PWH laboratory
(targeting both NSP-1 and the enve-
lope glycoprotein [E1] gene). AnLETTERS
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additional serum sample taken on day
8 of illness, received by PHLS only,
was also positive for chikungunya
RNA. Both laboratories confirmed
RT-PCR results by sequencing. At
PWH, phylogenetic analysis was per-
formed to determine the likely origin
of the virus. In-house immunofluores-
cent slide serologic assays developed
at PHLS found chikungunya immuno-
globulin G (IgG) titers <10, 160, and
320 in the serum samples taken on
days 2, 6, and 8 of illness, respective-
ly, and detected chikungunya IgM in
the day 8 serum. The acute cytokine
immunologic response to this virus
was also tested (online Appendix
available from http://www.cdc.gov/
ncidod/EID/vol12no11/06-0574_
app.htm). 
Sequencing and phylogenetic
analysis was consistent with an
imported infection, almost certainly
originating from the current chikun-
gunya outbreaks in the Indian Ocean.
Phylogenetic analyses of the NSP-1
and E1 regions, indicated that this
virus is most closely related to previ-
ous African rather than South-east
Asian chikungunya viruses (see online
Appendix Figures 1 and 2, available
from http://www.cdc.gov/ncidod/EID/
vol12no11/06-0574_appG1.htm and
http://www.cdc.gov/ncidod/EID/
vol12no11/06-0574_appG2.htm). The
persistence of viremia up to at least
day 8 of illness was unusual. Standard
texts state that viremia may be present
during the first 2–4 days of illness,
with neutralizing antibodies appearing
by days 5–7 (3).
The most striking finding from the
cytokine analysis (Table) is the high
level of interferon-γ (IFN-γ)– inducible
protein-10 (IP-10/CXCL-10), up to 26
and 16 times the upper limit of the nor-
mal range at days 2 and 6 after disease
onset, respectively. Serum concentra-
tions of interleukin-8 (IL-8), monocyte
chemoattractant protein (MCP) 1
(MCP-1) and monokine induced by
IFN-γ (MIG/ CXCL9) are also elevat-
ed in both samples. Notably, serum
IFN-γ, tumor necrosis factor-α (TNF-
α), and IL-1β, 6, 10, and 12 concentra-
tions remain within normal limits in
both samples, although the concentra-
tions at local inflammatory sites (e.g.,
joints) are unknown. CXCL10 and
MCP-1/CCL2 concentrations de-
creased during clinical recovery. Thus,
the cytokine profile demonstrates that
the levels of Th1 chemokine CXCL10
was highly elevated and that the levels
of chemokines IL-8/CXCL8, CCL2,
and CXCL9 were moderately elevated.
In contrast, IFN-γ and other inflamma-
tory/Th2 cytokines were not elevated
during the illness.
Interpretation of the significance of
these cytokine results is necessarily
speculative. Some comparison can be
made with other viral infections. In
severe acute respiratory syndrome–
associated coronavirus (SARS-CoV)
(4,5) and H5N1 influenza (6) infec-
tions, very high blood levels of
CXCL10 and moderately high CCL2,
CXCL9, and CXCL8 concentrations,
or their enhanced expressions in vitro,
have been reported. In dengue fever,
which has similar clinical manifesta-
tions as chikungunya fever, only ele-
vated CXCL8, IL-6, IL-10, and   TNF-
γ concentrations have been shown
consistently (7,8), although CXCL10
expression has not been studied. 
The function of CXCL10 is to act
as a chemoattractant for Th1 cells in
the activation of cell-mediated immune
response. Its expression can be up-reg-
ulated by the Th1 cytokine IFN-γ dur-
ing acute inflammation. CXCL10 has
been implicated in the pathogenesis of
SARS-CoVand H5N1 influenza infec-
tions, in which persistently high
CXCL10 concentrations seem to cor-
relate with disease severity and pro-
gression (4–6). CCL2, CXCL9, and
CXCL8, have also been found to have
a pathogenic role in H5N1 influenza,
SARS-CoV, and dengue infections.
Notably, the level of antiviral cytokine
IFN-γ was not elevated in our chikun-
gunya case, though admittedly, this is
only 1 case. This finding may represent
a way that the chikungunya virus
evades host defenses and may provide
a rationale for the use of IFN as a ther-
apeutic option (9). Such IFN therapy
has been suggested and tried, experi-
mentally, for SARS-CoV (5) and
dengue infections (10).
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Screening
Laboratory
Requests 
To the Editor: In August 1999, the
Laboratory Response Network (LRN)
was established to better integrate and
improve laboratory capacity for
responding to public health threats
(1). However, while experts have
focused on clinical indications for
testing for agents of bioterrorism, lab-
oratory methods for microbial identi-
fication, and needs for integrated
communication networks (2–4), little
attention has been given to how sen-
tinel laboratories can effectively
screen clinicians’ requests for testing
pathogens designated as global health
threats.
In times of crisis, clinicians often
pressure laboratorians to perform test-
ing for patients whose probability for
disease is very low or for nonvalidat-
ed sample types. In 2001, a few cases
of anthrax triggered large numbers of
nationwide requests to test nasal
swabs for Bacillus anthracis despite
the absence of data to support this
clinical practice outside epidemiolog-
ic investigations (5). Similarly, a
false-positive result for severe acute
respiratory syndrome (SARS) in 2003
from the National Microbiology
Laboratory in Canada created public
alarm that SARS was reemerging,
when the virus was actually that of a
common respiratory illness in a nurs-
ing home (6). The problem is further
complicated when laboratories other
than the LRN lack standardization,
have greater access to nucleic acid
amplification-based testing, and
develop tests for global health threats
outside a quality-regulated system.
False-positive results caused by con-
tamination or cross-reactivity with a
microorganism of low virulence can
disrupt a public health system,
adversely affect patient care, and
increase costs (6–8); false-negative
results may prompt clinicians to
discontinue containment procedures
and potentially risk transmitting a vir-
ulent microorganism. At our sentinel
laboratory, we recognized these chal-
lenges and took steps to promote judi-
cious use of testing for agents desig-
nated as global health threats. We
report use of an algorithm to evaluate
test requests for SARS-associated
coronavirus and highly pathogenic
avian influenza H5N1; however, the
algorithm can be used to screen test-
ing requests for any pathogen that has
potential to threaten public health.
During outbreaks of SARS and
H5N1, a laboratory protocol was
established to notify the on-call labo-
ratory professional when a sample
was received for testing for 1 of these
pathogens (Figure). The protocol
required the laboratorian to communi-
cate directly with the clinician, using
a script with questions based on crite-
ria established by the Centers for
Disease Control and Prevention, to
determine the medical necessity for
testing (9,10). Samples from patients
not meeting these criteria were reject-
ed. Testing for SARS used an in-
house real-time PCR assay with a
standard laboratory protocol. Samples
accepted for H5N1 testing were
screened by a nonspecific hemagglu-
tinin influenza PCR assay and, if
results were positive, were to be for-
warded to an LRN laboratory.
Positive results were to be reported
only after confirmation by an LRN
laboratory. Laboratory professionals
were specifically trained about the
sensitivity, specificity, positive pre-
dictive value, and negative predictive
value of test methods in relation to
sample type, time between symptom
onset and specimen collection, and
disease prevalence.
Of 41 samples (40 SARS and 1
H5N1) received for testing, 26 (63%)
samples were not tested because clini-
cian responses failed to satisfy the
screening criteria. The remaining 15
(37%) samples met criteria for testing
and all had negative results. In the